162 related articles for article (PubMed ID: 24841869)
1. Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni').
Brandt SD; Baumann MH; Partilla JS; Kavanagh PV; Power JD; Talbot B; Twamley B; Mahony O; O'Brien J; Elliott SP; Archer RP; Patrick J; Singh K; Dempster NM; Cosbey SH
Drug Test Anal; 2014; 6(7-8):684-95. PubMed ID: 24841869
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3',4'-methylenedioxy-4-methylaminorex (MDMAR).
McLaughlin G; Morris N; Kavanagh PV; Power JD; Twamley B; O'Brien J; Talbot B; Dowling G; Mahony O; Brandt SD; Patrick J; Archer RP; Partilla JS; Baumann MH
Drug Test Anal; 2015 Jul; 7(7):555-64. PubMed ID: 25331619
[TBL] [Abstract][Full Text] [Related]
3. The psychostimulant (±)-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters.
Maier J; Mayer FP; Luethi D; Holy M; Jäntsch K; Reither H; Hirtler L; Hoener MC; Liechti ME; Pifl C; Brandt SD; Sitte HH
Neuropharmacology; 2018 Aug; 138():282-291. PubMed ID: 29908239
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR.
Rickli A; Kolaczynska K; Hoener MC; Liechti ME
Neurotoxicology; 2019 May; 72():95-100. PubMed ID: 30776375
[TBL] [Abstract][Full Text] [Related]
5. A validated, sensitive HPLC-MS/MS method for quantification of cis-para-methyl-4-methylaminorex (cis-4,4'-DMAR) in rat and human plasma: application to pharmacokinetic studies in rats.
Lucchetti J; Marzo CM; Di Clemente A; Cervo L; Gobbi M
Drug Test Anal; 2017 Jun; 9(6):870-879. PubMed ID: 27509066
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers.
McLaughlin G; Baumann MH; Kavanagh PV; Morris N; Power JD; Dowling G; Twamley B; O'Brien J; Hessman G; Westphal F; Walther D; Brandt SD
Drug Test Anal; 2018 Sep; 10(9):1404-1416. PubMed ID: 29673128
[TBL] [Abstract][Full Text] [Related]
7. 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4'-DMAR, 4,4'-dimethylaminorex): availability, prevalence of use, desired effects and acute toxicity.
Glanville J; Dargan PI; Wood DM
Hum Psychopharmacol; 2015 May; 30(3):193-8. PubMed ID: 25784180
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV).
Marusich JA; Antonazzo KR; Wiley JL; Blough BE; Partilla JS; Baumann MH
Neuropharmacology; 2014 Dec; 87():206-13. PubMed ID: 24594476
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N-methoxy positional isomer, N-methoxymephedrone.
McLaughlin G; Morris N; Kavanagh PV; Power JD; Dowling G; Twamley B; O'Brien J; Talbot B; Walther D; Partilla JS; Baumann MH; Brandt SD
Drug Test Anal; 2017 Mar; 9(3):358-368. PubMed ID: 27524685
[TBL] [Abstract][Full Text] [Related]
10. Brain Disposition of
Lucchetti J; Marzo CM; Passoni A; Di Clemente A; Moro F; Bagnati R; Gobbi M; Cervo L
J Pharmacol Exp Ther; 2017 Jun; 361(3):492-500. PubMed ID: 28404688
[No Abstract] [Full Text] [Related]
11. Fluorinated phenmetrazine "legal highs" act as substrates for high-affinity monoamine transporters of the SLC6 family.
Mayer FP; Burchardt NV; Decker AM; Partilla JS; Li Y; McLaughlin G; Kavanagh PV; Sandtner W; Blough BE; Brandt SD; Baumann MH; Sitte HH
Neuropharmacology; 2018 May; 134(Pt A):149-157. PubMed ID: 28988906
[TBL] [Abstract][Full Text] [Related]
12. Genotoxicological Characterization of (±)cis-4,4'-DMAR and (±)trans-4,4'-DMAR and Their Association.
Lenzi M; Gasperini S; Cocchi V; Tirri M; Marti M; Hrelia P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628658
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Three Novel 4-Methylaminorex Derivatives Applied as Designer Drugs.
Seibert E; Kunert O; Pferschy-Wenzig EM; Schmid MG
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144500
[TBL] [Abstract][Full Text] [Related]
14. Effects of N-Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related Behavior.
Battisti UM; Sitta R; Harris A; Sakloth F; Walther D; Ruchala I; Negus SS; Baumann MH; Glennon RA; Eltit JM
ACS Chem Neurosci; 2018 Jul; 9(7):1829-1839. PubMed ID: 29697951
[TBL] [Abstract][Full Text] [Related]
15. N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.
Solis E; Partilla JS; Sakloth F; Ruchala I; Schwienteck KL; De Felice LJ; Eltit JM; Glennon RA; Negus SS; Baumann MH
Neuropsychopharmacology; 2017 Sep; 42(10):1950-1961. PubMed ID: 28530234
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a recently detected halogenated aminorex derivative: para-fluoro-4-methylaminorex (4'F-4-MAR).
Fabregat-Safont D; Carbón X; Ventura M; Fornís I; Hernández F; Ibáñez M
Sci Rep; 2019 Jun; 9(1):8314. PubMed ID: 31165778
[TBL] [Abstract][Full Text] [Related]
17. Cocaine-stimulus generalization to two new designer drugs: methcathinone and 4-methylaminorex.
Young R; Glennon RA
Pharmacol Biochem Behav; 1993 May; 45(1):229-31. PubMed ID: 8516363
[TBL] [Abstract][Full Text] [Related]
18. 2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α
Halberstadt AL; Brandt SD; Walther D; Baumann MH
Psychopharmacology (Berl); 2019 Mar; 236(3):989-999. PubMed ID: 30904940
[TBL] [Abstract][Full Text] [Related]
19. [Structure Analysis and Characterization of Aminorex Analogue 4'-F-4-MAR].
Liu CM; Hua ZD; Jia W
Fa Yi Xue Za Zhi; 2020 Oct; 36(5):677-681. PubMed ID: 33295170
[TBL] [Abstract][Full Text] [Related]
20. The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue.
Marusich JA; Antonazzo KR; Blough BE; Brandt SD; Kavanagh PV; Partilla JS; Baumann MH
Neuropharmacology; 2016 Feb; 101():68-75. PubMed ID: 26362361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
